Literature DB >> 29276236

Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.

Senir Turan1, Scot Walker2.   

Abstract

Rheumatoid arthritis (RA) is a disease where the immune system attacks the linings of the joints, resulting in joint pain, stiffness, swelling, and destruction. Although many products are available for the treatment of RA, limitations such as adverse reactions and tolerance greatly affect adherence. Many of the current biologic disease-modifying antirheumatic drugs on the market are injectables, leaving a void to be filled for a product that can be taken orally. The most advanced of these approaches, the Janus kinase (JAK) inhibitors, are oral drugs that have not only made a breakthrough in RA, but also other skin conditions.

Entities:  

Keywords:  formulary management/P&T; intravenous therapy; rheumatology

Year:  2017        PMID: 29276236      PMCID: PMC5735748          DOI: 10.1177/0018578717729668

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  5 in total

1.  Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).

Authors:  R Westhovens; P C Taylor; R Alten; D Pavlova; F Enríquez-Sosa; M Mazur; M Greenwald; A Van der Aa; F Vanhoutte; C Tasset; P Harrison
Journal:  Ann Rheum Dis       Date:  2016-12-19       Impact factor: 19.103

Review 2.  Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.

Authors:  Shingo Nakayamada; Satoshi Kubo; Shigeru Iwata; Yoshiya Tanaka
Journal:  BioDrugs       Date:  2016-10       Impact factor: 5.807

Review 3.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Authors:  Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-11-06       Impact factor: 4.794

4.  Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.

Authors:  Maxime Dougados; Désirée van der Heijde; Ying-Chou Chen; Maria Greenwald; Edit Drescher; Jiajun Liu; Scott Beattie; Sarah Witt; Inmaculada de la Torre; Carol Gaich; Terence Rooney; Douglas Schlichting; Stephanie de Bono; Paul Emery
Journal:  Ann Rheum Dis       Date:  2016-09-29       Impact factor: 19.103

5.  Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.

Authors:  Vibeke Strand; Joel M Kremer; David Gruben; Sriram Krishnaswami; Samuel H Zwillich; Gene V Wallenstein
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-04       Impact factor: 4.794

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.